drugset / Trial / NCT00422903
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Evaluate the percentage of clinical objective responses (cOR) in patients with HER2 negative early breast cancer treated with pre operative (neoadjuvant)lapatinib and letrozole
Timeline
- Start
- 2007-04
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 1500 mg | Oral |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |